Sugi Predict

Sugi Predict / Compounds / SCHEMBL1064841

SCHEMBL1064841

SCHEMBL1064841

CSc1nc(Nc2c(F)cccc2F)c(C=O)c(-c2ccc(F)cc2C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AB1 P08238 5/20 0.44
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ RXFP1 Q9HBX9 3/20 0.34
▸ MAPT P10636 3/20 0.34
▸ CTSA P10619 3/20 0.33
▸ LMNA P02545 4/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CTDSP1 Q9GZU7 1/20 0.31
▸ SRC P12931 2/20 0.31
▸ HDAC9 Q9UKV0 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ ABL1 P00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065963 0.93 HSP90AB1 (0.45) HSP90AB1MAPK1HTTCA1CA2
SCHEMBL1063918 0.89 HSP90AB1 (0.43) HSP90AB1MAPK1HTTCA1CA2
SCHEMBL4177087 0.86 HSP90AB1 (0.40) HSP90AB1MAPK1HTTRXFP1MAPT
SCHEMBL4177081 0.86 HSP90AB1 (0.40) HSP90AB1MAPK1HTTRXFP1MAPT
SCHEMBL27728879 0.86 CA1 (0.35) HSP90AB1MAPK1HTTCA1CA2
SCHEMBL1065995 0.85 HSP90AB1 (0.44) HSP90AB1MAPK1HTTCA1CA2
SCHEMBL4467853 0.85 CA1 (0.37) HSP90AB1CA1CA2CA7RXFP1
SCHEMBL1060727 0.85 CA1 (0.38) MAPK1HTTCA1CA2CA7
SCHEMBL29594311 0.83 MAPK14 (0.36) RXFP1CTSALMNAALDH1A1HDAC9
SCHEMBL28465739 0.83 MAPK14 (0.36) RXFP1CTSALMNAALDH1A1HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314934-B2 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates SMITHKLINE BEECHAM CORPORATION (US) 2008-01-01 — — US claimed
US-20050203109-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2005-09-15 — — US claimed
US-20040209901-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-10-21 — — US claimed
US-20040116697-A1 Novel compounds GLAXOSMITHKLINE LLC 2004-06-17 — — US claimed
EP-4159212-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2023-04-05 — — EP disclosed
US-20220282254-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD FULCRUM THERAPEUTICS INC (US) 2022-09-08 — — US disclosed
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD FULCRUM THERAPEUTICS INC (US) 2022-05-05 — — US disclosed
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2022-04-05 — — US disclosed
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2020-12-10 — — US disclosed
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2019-07-09 — — US disclosed
US-20190105312-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed
WO-2007059500-A2 NOVEL PROCESS AND FORMULATIONS GLAXO GROUP LIMITED (GB) 2007-05-24 — — WO disclosed
WO-2006110298-A2 8-ALKYL/ARYL-4-ARYL-2-N- (ALKYLAMINO)-N'-SUBSTITUTED-N'-CYANOGUANIDINO-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND USE THEREOF GLAXO GROUP LIMITED (GB) 2006-10-19 — — WO disclosed
US-20060217401-A1 e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis GLAXO GROUP LIMITED (GB) 2006-09-28 — — US disclosed
US-20050203109-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2005-09-15 — — US disclosed
US-20040209901-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-10-21 — — US disclosed
US-20040116697-A1 Novel compounds GLAXOSMITHKLINE LLC 2004-06-17 — — US disclosed
EP-1333833-A2 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2003-08-13 — — EP disclosed
WO-2002059083-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1715/4885MAPK1 175/4885HTT 2761/4885
US-20060217401-A1 e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis MAPK8, MAPKAPK2, MAPK7 HSP90AB1 1079/4885MAPK1 6/4885HTT 3459/4885
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, RHOXF2 HSP90AB1 1627/4885MAPK1 143/4885HTT 3064/4885
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1899/4885MAPK1 172/4885HTT 2868/4885
US-20220282254-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1715/4885MAPK1 175/4885HTT 2761/4885
US-20190105312-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1715/4885MAPK1 175/4885HTT 2761/4885
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1715/4885MAPK1 175/4885HTT 2761/4885
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 HSP90AB1 1715/4885MAPK1 175/4885HTT 2761/4885
US-20040209901-A1 Novel compounds MAPKAPK2, MAPKAPK3, MAPK7 HSP90AB1 451/4885MAPK1 12/4885HTT 4851/4885
US-20050203109-A1 Novel Compounds MAPKAPK2, CREBBP, CDC42BPB HSP90AB1 466/4885MAPK1 17/4885HTT 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.